semaglutide for heart The weight-loss drug Wegovy lowered attack risk in a large trial GLP-1 agonists like Ozempic may

Eiichiro Satake Kevin Duffin Jonathan Wilson Fergus Fleming Anna Nowak-Szwed Pavo Imre #PrecisionMedicine #Olink #proteomics #Tirzepatide Diabetes Conference Abstract | June 5, 2026 Using the custom Joslin Kidney Panel (JKP), an #Olink Focus 21-marker #proteomics panel developed by Olink for Joslin Diabetes Center, researchers from Harvard Medical School/Joslin Diabetes Center and Eli Lilly and Company showed that treatment with the dual GLP-1/GIP receptor agonist tirzepatide (#Mounjaro) significantly reduced circulating protein #biomarkers associated with progression to end-stage #kidney disease (#ESKD) in patients with type 2 diabetes (#T2D)

This allows us to review your health history, goals, and determine which peptides are appropriate for you

What if my Ozempic gets too hot

We want to inform you of an important update regarding Rybelsus (oral semaglutide) and how this may affect your current or future prescription from January 2026 onwards

Jul 1, 2026 For Licensed Providers